Table 4 Multivariable Cox Proportional Hazards modelling of Time to Escalation in the training and validation population.
From: Delineating COVID-19 subgroups using routine clinical data identifies distinct in-hospital outcomes
Covariate | Training | Validation | ||||||
|---|---|---|---|---|---|---|---|---|
HR | Lower 95% | Upper 95% | p-value | HR | Lower 95% | Upper 95% | p-value | |
Age | 1.01 | 1.00 | 1.02 | 0.01 | 1.01 | 1.00 | 1.01 | 0.29 |
Sex | 0.80 | 0.62 | 1.03 | 0.08 | 0.59 | 0.45 | 0.78 | 0.00 |
Subtype 1 | 4.05 | 2.08 | 7.88 | 0.00 | 2.69 | 1.32 | 5.47 | 0.01 |
Subtype 2 | 3.73 | 1.85 | 7.49 | 0.00 | 2.77 | 1.41 | 5.45 | 0.00 |
Subtype 3 | 5.04 | 2.37 | 10.74 | 0.00 | 2.58 | 1.28 | 5.17 | 0.01 |
Weighted stage | 2.74 | 1.35 | 5.56 | 0.01 | 2.99 | 1.58 | 5.66 | 0.00 |
Subtype 1: wstage | 0.44 | 0.22 | 0.90 | 0.02 | 0.39 | 0.20 | 0.75 | 0.00 |
Subtype 2: wstage | 0.42 | 0.21 | 0.86 | 0.02 | 0.42 | 0.22 | 0.80 | 0.01 |
Subtype 3: wstage | 0.35 | 0.17 | 0.72 | 0.00 | 0.38 | 0.20 | 0.73 | 0.00 |
